In medicine, treatment goals set by physicians might differ from patient priorities. Although normalisation of laboratory parameters is a target supported by outcomes data, patient perspectives ...

Learn about Primary Biliary Cholangitis, its causes, symptoms like fatigue and itching and treatment options including medications and possible liver transplant ...

In this video interview, Ahmad Anouti, MD, a pediatric resident at UT Southwestern Medical Center, highlights disparities in primary biliary cholangitis care and ways to overcome them.He noted ...

—Researchers provide the most comprehensive genetic synopsis of primary biliary cholangitis to date, identifying 44 risk-associated variants with strong evidence for novel genome-wide significant loci ...

Once clinical suspicion has been established for primary biliary cholangitis (PBC), the "serologic hallmark" of the autoimmune disease are anti-mitochondrial antibodies (AMA), present in approximately ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Content developed independently by our editors and supported by our partners. Carrington Garvin had been living the fun-packed life of a typical 21-year-old in Las Vegas—dating, working for a gaming ...

Findings showed a statistically significantly greater proportion of saroglitazar-treated patients achieved a biochemical response vs placebo (treatment difference, 48.5%; P .001). Topline data were ...

Australians living with chronic liver disease will soon have access to a new cheaper medicine on the Pharmaceutical Benefits Scheme (PBS).Elafibranor ...

EXTON, PA, July 17, 2025 (GLOBE NEWSWIRE) -- The treatment landscape for primary biliary cholangitis (PBC) has undergone a marked transformation over the past year, driven by the recent approvals of ...

(RTTNews) - Gilead Sciences Inc. (GILD) announced that the U.S. Food and Drug Administration has granted accelerated approval for Livdelzi (seladelpar) to treat primary biliary cholangitis or PBC.

The accelerated approval was based primarily on data from the pivotal placebo-controlled Phase 3 RESPONSE study. In the study, 62% of participants taking Livdelzi achieved the primary endpoint of ...